Acceleron Pharma has announced that the Gynecologic Oncology Group (GOG) has sponsored its phase 2 study of dalantercept. Patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer are taking part in the ...
Acceleron Pharma, a developer of protein therapeutics for cancer and orphan diseases, has entered into a collaboration agreement to deploy QUMAS' DocCompliance to manage all of its regulatory documents, following an extensive vendor ...
Tags: Acceleron Pharma, cancer, orphan diseases, collaboration agreement